ReviewNeurology. Clinical practice2017
Aminopyridines for the treatment of neurologic disorders.
Review in Neurology. Clinical practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Episodic Ataxias: Primary and Secondary Etiologies, Treatment, and Classification Approaches.Tremor and other hyperkinetic movements (New York, N.Y.) · 2023Pooled it
- The role of transcranial direct current stimulaton on ataxia: a scoping review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Long-term response to aminopyridines in a cohort of patients with ataxia associated with downbeat nystagmus due to the FGF14 GAA expansion.Neurologia · 2026Article
- Control of site-specific deprotonation through mechanochemical interconversion of two ionic cocrystal forms of resveratrol.Journal of materials chemistry. B · 2026Article
- Effect of Aminopyridines on Oculomotor Dysfunction in Anti-GAD Ataxia: A Brief Report.Cerebellum (London, England) · 2025Article
- Downbeat Nystagmus: Case Report, Updated Review, Therapeutics, and Neurorehabilitation.Brain sciences · 2025Article
- Bilateral vestibulopathy in Alexander disease type II- a case report.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2025Article
- Neurovisual Training With Acoustic Feedback: An Innovative Approach for Nystagmus Rehabilitation.Archives of rehabilitation research and clinical translation · 2024Article
- Seizures Triggered by Systemic Administration of 4-Aminopyridine in Rats Lead to Acute Brain Glucose Hypometabolism, as Assessed by [International journal of molecular sciences · 2024Article
- Pharmacological Treatment of Acute Unilateral Vestibulopathy: A Review.Journal of audiology & otology · 2024Review
- 4-Aminopyridine improves real-life gait performance in SCA27B on a single-subject level: a prospective n-of-1 treatment experience.Journal of neurology · 2023Article
- Non-coding variants in VAMP2 and SNAP25 affect gene expression: potential implications in migraine susceptibility.The journal of headache and pain · 2023Article
- Experimental Treatment with Edaravone in a Mouse Model of Spinocerebellar Ataxia 1.International journal of molecular sciences · 2023Article
- 4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.Neurochemical research · 2023Article
- Simulations of active zone structure and function at mammalian NMJs predict that loss of calcium channels alone is not sufficient to replicate LEMS effects.Journal of neurophysiology · 2023Article
- Two-muscle surgical treatment of a compensatory head tilt in an adult with acquired downbeat nystagmus.Proceedings (Baylor University. Medical Center) · 2023Article
- 4-Aminopyridine Induces Nerve Growth Factor to Improve Skin Wound Healing and Tissue Regeneration.Biomedicines · 2022Article
- Article
- Overcoming presynaptic effects of VAMP2 mutations with 4-aminopyridine treatment.Human mutation · 2020Article
- Episodic Ataxias: Faux or Real?International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo identify the different indications for the treatment of neurologic disorders with the potassium channel blockers 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP). RECENT
findings4-AP is an effective symptomatic treatment for downbeat nystagmus (DBN), episodic ataxia type 2 (EA2) (5-10 mg TID), and impaired gait in multiple sclerosis (MS) (10 mg BID). 3,4-DAP (5 mg/d-20 mg TID) improves symptoms in Lambert-Eaton myasthenic syndrome (LEMS) (randomized placebo-controlled trials for all 4 entities). 4-AP may also be effective in cerebellar gait ataxia of different etiologies (2 case series), upbeat nystagmus, and limb ataxia in MS (single cases). In the recommended dosages, they are well tolerated. The assumed mode of action is a blockade of mainly Kv SUMMARY: There is sufficient evidence that APs are indicated for the symptomatic treatment of DBN, EA2, gait ataxia due to MS and cerebellar disorders, and LEMS with a reasonable risk-benefit profile.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.